An analysis of barbiturate-induced eating and drinking in the rat

Different patterns of behavior produced by haloperidol, pentobarbital, and dantrolene in tests of unconditioned locomotion and operant responding

Three motor-impairing drugs with different putative mechanisms of action (haloperidol 0.00, 0.075, 0.15, 0.30 mg/kg IP; pentobarbital 0.00, 4.5, 9, 12 mg/kg IP; and dantrolene 0.00, 5, 7.5, 10 mg/kg IP) produced strikingly similar patterns of dose-dependent attenuation in unconditioned locomotor behavior. However, the same drugs and doses produced highly divergent patterns of disruption when tested using different groups of rats in a food-rewarded operant task, which included both response initiation and maintenance components (FR1-FR1 two lever chain). Haloperidol animals began the session as fast as vehicle animals and slowed dose-dependently across trials; pentobarbital animals started off significantly slower than controls but soon achieved comparable speeds; and dantrolene animals were slower throughout the session. These results suggest that the observed neuroleptic-induced deterioration in responding over trials, especially in response initiation, was not simply a result of motoric disruption. Rather, the profile of this deterioration is consistent with the anhedonia hypothesis of neuroleptic action and supports the view that dopamine neurons are involved in the biological basis of food reward.

The role of reward pathways in the development of drug dependence

In commenting on the discovery of "opiate" receptors, Goldstein (1976) said: "It seemed unlikely, a priori, that such highly stereospecific receptors should have been developed by nature to interact with alkaloids from the opium poppy" (p. 1081). Endogenous opioid peptides and opioid receptor systems have now been identified in invertebrates that are unlikely to have had ancestors exposed to opium poppies (Kavaliers et al., 1983; Kream et al., 1980; Leung and Stefano, 1984; Stefano et al., 1980). Moreover, endogenous opioids play a role in stress-induced feeding in the slug (Kavaliers and Hirst, 1986) just as they play a role in stress-induced feeding in rodents (Lowy et al., 1980; Morley and Levine, 1980). If we are to understand the actions of opiates and other drugs of abuse we must understand them in terms of their abilities to interact with neural systems that evolved in the service of primitive biological functions, long before any serious incidence of addiction itself. The most primitive axes of the biological substrates of behavior are the axes of approach and withdrawal. Addictive drugs appear to be able to activate the mechanisms of approach, which is termed "positive reinforcement" and to inhibit the mechanisms of withdrawal, which is termed "negative reinforcement." Anatomically distinct sets of pathways have evolved to serve these two forms of reward. Activation of the medial forebrain bundle and associated structures serves positive reinforcement and induces forward locomotion. Approach and forward locomotion are the unconditioned responses to positive reinforcing stimuli such as food and sex partners, and approach to environmental objects and positive reinforcement is induced by electrical stimulation of this structure. The locomotor stimulating effects and the positive reinforcing effects of opiates and psychomotor stimulants result from their activation of this mechanism; stimulants activate the mechanism at the level of dopaminergic synapses of the nucleus accumbens, frontal cortex, and perhaps other forebrain structures, while opiates activate the system at two points: at the level of the dopaminergic synapse and at the level of the afferents to the dopaminergic cell bodies. Ethanol, nicotine, caffeine and phencyclidine stimulate both locomotor activity and dopamine turnover, but their sites of interaction with reward pathways have not yet been identified. Benzodiazepines and barbiturates stimulate locomotor activity without stimulating dopamine turnover; they may interact with reward pathways at a synapse efferent to the dopaminergic link in the pathways.(ABSTRACT TRUNCATED AT 400 WORDS)

Experimental manipulations of eating: advances in animal models for studying anorectic agents

The material set out in this text has been designed to show the wide range of procedures which have the capacity to modify eating behavior--to produce hyper- or hypophagia, to alter the profile of eating patterns, or to adjust dietary preferences and selection. Accordingly, in investigating anorectic drugs it seems necessary to observe the effects of drug actions in a variety of experimental models. This strategy will provide a more complete description of the effect of a drug, will throw light on the mechanism of action, and will provide a more realistic base for predicting the effects of drugs in man.

Specific antagonism by RO 15-1788 of benzodiazepine-induced increases in food intake in rhesus monkeys

Food intake of rhesus monkeys was limited to a single daily 2 hr session of banana flavored pellet availability, seven days a week. Following stabilization of intake, the effects of intragastric bromazepam, diazepam and pentobarbital, when given alone, were determined by delivering a dose twice weekly, 60 min before the session. Dose-dependent increases in food intake were observed with the following descending order of potencies: bromazepam, diazepam and pentobarbital. RO 15-1788 (0.5-1.0 mg/kg, IM), when given alone, five min before the session had no effect on food intake. When given in combination with bromazepam and diazepam, RO 15-1788 completely blocked the increases in food intake observed when the benzodiazepines were given alone. The specificity of this antagonism was shown by the failure of RO 15-1788 to alter the food intake increases induced by pentobarbital. These results confirm and extend previous reports of the specific antagonism of benzodiazepine behavioral effects by RO 15-1788 to an additional species and another behavioral effect of benzodiazepines.

Pentobarbital-induced drinking does not rely on a renal dipsogen

Injections of pentobarbital have been shown to produce drinking in both deprived and nondeprived rats and a number of other studies have shown that pentobarbital is a potent renin releasor. Since renin has been shown to be involved in thirst regulatory mechanisms and since the dipsogenic actions of other renin-releasing agents have been blocked by nephrectomy, we sought to determine whether or not pentobarbital-induced drinking relies on a renal dipsogen. Rats were either "sham" operated or nephrectomized under ether anesthesia. Five to six hours later, animals in each group were injected with either 9.5 mg/kg pentobarbital sodium or vehicle, and intakes were measured 60 minutes later. Statistical analysis of water intakes indicated that pentobarbital produced significant drinking in both control operated and in nephrectomized rats, and that the intakes in these two groups did not differ. These results indicate that pentobarbital-induced drinking is not secondary to increased plasma renin activity and may suggest the involvement of central mechanisms in the drinking response.

Effects of naloxone and naltrexone on the increased water intake and drinking duration in phenobarbitone-treated rats

In two experiments, phenobarbitone sodium (30 mg/kg) reliably enhanced water consumption and extended the duration of drinking in 24h water-deprived male rats. The opiate receptor antagonists naloxone (0.1-10 mg/kg) and naltrexone (0.1-10 mg/kg) both decreased water intake and reduced the duration of drinking. When the barbiturate was given in conjunction with either naloxone or naltrexone, phenobarbitone and the opiate antagonist exerted opposite effects on the two measures of drinking. While it was true that both opiate antagonists reduced water intake and drinking duration in barbiturate-treated animals, the barbiturate-induced enhancement of drinking was in no way modified by concurrent opiate antagonist treatment. Hence, the effects of phenobarbitone and of the two opiate antagonists upon the drinking measures appeared to be quite independent. There was no evidence, therefore, that the effects of phenobarbitone upon drinking were related to endogenous opioid mechanisms. The possible contrast between benzodiazepine- and barbiturate-induced hyperdipsia is briefly considered in the light of these results.

GABA and endorphin mechanisms in relation to the effects of benzodiazepines on feeding and drinking

Behavioural actions of benzodiazepines have a number of significant characteristics. Anxiolytic effects are demonstrable both clinically and experimentally; in addition, there is excellent evidence for a reinforcing effect of these compounds, and a direct involvement in ingestional responses. This review focusses on the effects of benzodiazepines on the latter feeding and drinking responses. A necessary mediator of benzodiazepine action in the central nervous system appears to be the facilitation of inhibitory GABAergic neurotransmission. It follows, therefore, that behavioural consequences of benzodiazepine action may depend crucially on enhanced GABAergic activity in the brain. Evidence for some involvement of GABAergic mechanisms in the control of feeding and drinking responses is reviewed. Only a few data are so far available to link benzodiazepines effects on ingestional behaviour directly to GABAergic transmission. A major current theme in the psychopharmacology of feeding and drinking behaviour is the possible involvement of endogenous opioid peptides. There is a strong suggestion in the experimental data that there are links between benzodiazepine and endorphinergic mechanisms in relation to ingestional responses. A promising future line of approach appears to be a delineation of benzodiazepine-GABA-endorphin interrelations in the control of food and water consumption.

Drugs and taste aversion

The literature on the effects of drugs on the acquisition and the magnitude of taste aversion is reviewed and discussed. Then, the results of a series of experiments on the effects of phenobarbital and related drugs on taste aversion are reported. A standard taste aversion model was used in all experiments; test drugs were injected prior to drinking in a one bottle situation on the first test day following the taste aversion treatment. Phenobarbital in doses ranging from 20 to 80 mg/kg significantly attenuated taste aversion induced by lithium chloride (LiCl) and x-radiation, the maximal effect occurred with the 60 mg/kg dose. The attenuating effect was found to be dependent upon the magnitude of the aversion to the sapid solution. Phenobarbital completely abolished aversion produced by 0.375 mEq LiCl while the attenuation effect decreased linearly with higher doses of LiCl. Results also indicate that phenobarbital's attenuating effect cannot be solely attributed to its dipsogenic characteristic or to its state dependent learning effect. Attenuation of LiCl aversion to a saccharin solution was also observed following single doses of amobarbital, 30 mg/kg, pentobarbital, 15 mg/kg, and chloropromazine, 0.75 mg/kg. Taste aversion was not affected by other doses of those drugs or by hexobarbital, barbital, and chlordiazepoxide. Phenobarbital's attenuating effect on taste aversion is discussed in relation to other known behavioral and neurophysiological effects of the drug.

The taste aversion induction properties of two long duration barbiturates

The ability of sodium phenobarbital (60 mg/kg) and sodium barbital (80 mg/kg) to produce a taste aversion in 23 hr fluid deprived rats was examined using a discrimination or two bottle taste aversion task (0.125% sodium saccharin solution or water). The interaction of both barbiturates with the effects of 3.0 mEq/kg lithium chloride (LiCl) was also examined. Results indicate that phenobarbital treatment alone produces a stronger saccharin aversion than does barbital. Also, barbiturate treatment 24 hr after LICi administration does not attenuate saccharin avoidance, although phenobarbital treatment following LiCl administration was sufficient to induce a maximum aversion that did not extinguish after twenty days of continuous discrimination testing. These data suggest that the aversion inducing properties of the two barbiturates are dissimilar and that phenobarbital is the more effective agent in the production of saccharin aversion. In addition, barbiturate induced attenuation of conditioned taste aversion is apparently related to the periodic forced intake test model since it does not occur when a water and saccharin choice is available.

The effects of various barbiturates on LiCl induced taste aversion

The effects of various barbiturates on LiCl induced taste aversion were examined. Rats were adapted to a 23 hr and 50 min water deprivation schedule. On the Treatment Day, animals were offered a novel 0.125% saccharin solution and then administered 3.0 mEq/kg LiCl. The saccharin solution was presented again on three subsequent Test Days. Fifteen minutes prior to drinking on the first Test Day animals were injected subcutaneously with either 10, 30, and 50 mg/kg Amobarbital, 3, 9, and 15 mg/kg Pentobarbital, 40, 80, and 120 mg/kg Barbital, or 1, 3, and 9 mg/kg Hexobarbital. Results indicate that only 30 mg/kg of Amobarbital and 15 mg/kg of Pentobarbital significantly attenuated the magnitude of taste aversion.

Effects of phenobarbital on taste aversion induced by X-radiation

The effects of phenobarbital on taste aversion induced by X-radiation were examined. Rats were adapted to a 23 hr 50 min water deprivation schedule. On the Treatment Day animals were given a novel 0.125% Na saccharin solution during the 10 min drinking session and were then exposed to 100 rads of X-radiation. The saccharin solution was presented again on six subsequent Test Days. Phenobarbital in doses of 20, 40, 60 and 80 mg/kg was administered 15 min prior to drinking on the first Test Day. Results demonstrate that phenobarbital in all doses tested has a significant attenuating effect on radiation induced taste aversion.

The effects of phenobarbital on lithium chloride induced taste aversion

The dose related effects of phenobarbital on LiCl induced taste aversion were examined. Rats were adapted to a 23 hr 50 min water deprivation schedule. On the Treatment Day animals were offered a novel 0.125% saccharin solution during the 10 min drinking session and were then administered 3.0 mEq/kg LiCl. The saccharin solution was presented again on six subsequent Test Days. Sodium phenobarbital 20, 40, 60 and 80 mg/kg was administered 15 min prior to drinking on the first Test Day. Results indicated that all doses significantly attenuated taste aversion with the maximal effect occurring with the 60 mg/kg dose.